Can ketorolac (Toradol) be used in a patient with hypertension, and what blood pressure thresholds and monitoring are recommended?

Ketorolac (Toradol) and Blood Pressure

Ketorolac can be used cautiously in patients with hypertension, but requires close blood pressure monitoring throughout treatment and should be avoided in patients with uncontrolled hypertension or recent cardiovascular events.

Key Cardiovascular Concerns with Ketorolac

The FDA label explicitly warns that NSAIDs including ketorolac can cause new-onset hypertension or worsen pre-existing hypertension, which may contribute to increased cardiovascular events 1. This occurs through several mechanisms:

• Inhibition of vasodilatory prostaglandins (particularly PGI2/prostacyclin) that normally regulate vascular tone
• Increased systemic vascular resistance
• Blunted effectiveness of antihypertensive medications, particularly thiazide and loop diuretics, ACE inhibitors, and ARBs 1

Blood Pressure Monitoring Requirements

Monitor BP closely at initiation and throughout the entire treatment course 1. While no specific BP threshold is defined in the FDA label for contraindication, the clinical approach should be:

• Baseline BP assessment before starting ketorolac
• Daily BP monitoring during treatment, particularly in the first 48-72 hours
• Immediate discontinuation if significant BP elevation occurs (≥20 mmHg systolic or ≥10 mmHg diastolic increase from baseline)

Specific Clinical Scenarios Where Ketorolac Should Be Avoided

The FDA label provides clear guidance on high-risk situations 1:

1. Recent myocardial infarction: Avoid unless benefits clearly outweigh risks; if used, monitor for cardiac ischemia
2. Post-CABG surgery: Absolutely contraindicated (increased MI and stroke risk)
3. Severe heart failure: Avoid unless benefits outweigh risk of worsening heart failure; monitor closely if used
4. Uncontrolled hypertension: Use extreme caution or avoid entirely

Hemodynamic Profile Compared to Opioids

Interestingly, ketorolac demonstrates more favorable hemodynamic effects than morphine in perioperative settings. Studies show ketorolac causes no significant changes in cardiac output, mean arterial pressure, or pulmonary vascular resistance, whereas morphine decreases cardiac output and increases pulmonary vascular resistance 2, 3. This makes ketorolac potentially advantageous when hypotension is undesirable 4.

Practical Treatment Algorithm

For patients with controlled hypertension (BP <140/90 mmHg on treatment):

• Ketorolac may be used with close monitoring
• Check baseline BP and renal function
• Monitor BP daily during treatment
• Limit duration to ≤5 days (per FDA recommendations for all patients) 5
• Use lowest effective dose

For patients with elevated BP (130-139/80-89 mmHg) or stage 1 hypertension:

• Consider alternative analgesics first
• If ketorolac necessary, ensure BP monitoring every 4-6 hours initially
• Verify antihypertensive medications are optimized per current guidelines 6, 7

For patients with stage 2 hypertension (≥140/90 mmHg) or uncontrolled BP:

• Avoid ketorolac until BP is controlled
• Use alternative analgesics (acetaminophen, opioids if appropriate)

Important Caveats

• Duration matters: Keep treatment to ≤5 days to minimize adverse effects 5
• Dose matters: Higher doses (>60 mg/day) significantly increase risk of complications 1
• Age matters: Elderly patients (≥65 years) have higher risk of cardiovascular complications
• Drug interactions: Ketorolac may reduce effectiveness of ACE inhibitors, ARBs, and diuretics 1

The 2024 ESC and 2025 AHA/ACC hypertension guidelines emphasize targeting systolic BP to 120-129 mmHg in most treated patients 6, 7, making any medication that could elevate BP particularly problematic in achieving these goals.